Linking Ubiquitin Research to Drug Discovery

Cyclofluidic Logo


Ubiquigent and Cyclofluidic Limited, a leading medicinal chemistry company based on an innovative integrated discovery technology platform, entered into a collaboration in 2015 to develop novel targeted compound libraries that specifically target the ubiquitin system.

The aim of this collaboration is to design, develop and characterise small molecule compound libraries by combining two complimentary technology platforms: Ubiquigent’s DUBprofiler™ and Cyclofluidic’s CyclOps™.

The output of the collaboration will be a valuable source of novel targeted libraries that the companies will jointly commercialise. These libraries will provide new medicinal chemistry opportunities to support the identification of potent and selective compounds that target key members of the ubiquitin system.